Uma Borate, M.D., M.S.

Dr. Uma Borate is a distinguished hematologist specializing in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and clonal cytopenias of unknown significance. She received her Master of Science in Pathobiology and Molecular Medicine from the University of Cincinnati, and completed a fellowship in hematology/oncology at the University of Alabama.

As a member of the Leukemia Research Program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), her clinical and translational research focuses on novel therapeutics in myeloid diseases, particularly in the disease progression from cytopenia and early-stage MDS to AML. Dr. Borate is the principal investigator for numerous investigator-initiated clinical trials based on laboratory science, including a promising study exploring a novel combination of targeted therapies for myeloid malignancies. She is also the national lead and site investigator for several early-phase, industry-supported MDS and AML studies, addressing both upfront and relapsed/refractory disease. Her work has been published in peer-reviewed journals such as Nature Medicine, Oncotarget, Blood Advances, and Leukemia.

Dr. Borate founded a myeloid malignancy predisposition clinic at OSUCCC – James, focusing on clinical care and research for patients at high risk for myeloid malignancies due to hereditary germline mutations and acquired mutations resulting in clonal cytopenias. This clinic collaborates closely with genetic counselors to deliver the best evidence-based care for this patient population. Additionally, she is involved in developing several protocols for the National Cancer Institute (NCI) cooperative groups in MDS and AML, as well as for the newly established MPN group.

In her capacity as an associate professor in the Division of Hematology at The Ohio State University, and as the disease group leader for the MDS and MPN clinical trial disease group, Dr. Borate is at the forefront of advancing medical knowledge and patient care. She is a member of several prestigious professional organizations, including the Southwest Oncology Group, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.

Dr. Borate is committed to the care of her patients and believes in the power of teamwork to deliver the most advanced research and clinical treatments. She embodies the philosophy that collaborative efforts are key to achieving excellence in patient care and research, aligning with OSUCCC – James's mission to create a cancer-free world.